Patents Examined by Michael D. Pak
  • EGFR and c-Met fibronectin type III domain binding molecules
    Patent number: 10954284
    Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: March 23, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Mark Anderson, Ricardo Attar, Michael Diem, Linus Hyun, Steven Jacobs, Alastair King, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha
  • Immunity to folate receptors
    Patent number: 10948480
    Abstract: This document provides methods and materials related to assessing immunity to folate receptors. For example, methods and materials for assessing FR? immunity in a mammal are provided. This document also provides methods and materials related to stimulating immunity to folate receptors.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: March 16, 2021
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Keith L. Knutson, Lynn C. Hartmann, Kimberly R. Kalli, Christopher J. Krco
  • Tumor-specific anti-EGFR antibody and application thereof
    Patent number: 10927176
    Abstract: The present invention provides a tumor-specific anti-EGFR antibody and application thereof. The antibody can be used for preparing targeted antitumor drugs and tumor diagnosis drugs.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: February 23, 2021
    Assignee: CARSGEN THERAPEUTICS CO., LTD.
    Inventors: Huamao Wang, Bo Song
  • Exposed collagen-targeted fusion cytokine for immune modulation in invasive cancers and lesions of infections
    Patent number: 10913779
    Abstract: Provided herein are new compositions and methods to target pharmaceutical agents to pathological areas by utilizing fusion polypeptides. These fusion polypeptides contain two or more domains: (i) aptamer sequences that bind to exposed collagenous (XC-) proteins present in pathological areas, including cancerous and viral lesions, (ii) immunomodulators, such as cytokines, and optionally (iii) at least one linker joining the two domains or at the terminus of the polypeptide. In some cases, the linker is a rigid linker, e.g., a rigid helical linker. Also provided herein are methods of treating cancer and/or infectious diseases using the new fusion polypeptides.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: February 9, 2021
    Assignee: Counterpoint Biomedica LLC
    Inventors: Frederick L. Hall, Erlinda M. Gordon
  • Nanovesicle comprising heterodimeric G-protein coupled receptor, method for preparing nanovesicle, field effect transistor-based taste sensor comprising nanovesicle, and method for manufacturing taste sensor
    Patent number: 10914736
    Abstract: The present invention relates to a nanovesicle comprising a heterodimeric G-protein coupled receptor, a method for preparing the nanovesicle, a field effect transistor-based taste sensor comprising the nanovesicle, and a method for manufacturing the taste sensor. The field effect transistor based taste sensor functionalized by the nanovesicle comprising the heterodimer G-protein coupled receptor according to the present invention has excellent sensitivity and selectivity and may highly specifically detect a sweet taste substance in real time, by using the heterodimeric G-protein coupled receptor and the nanovesicle comprising the same.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: February 9, 2021
    Assignee: Seoul National University R&DB Foundation
    Inventors: Tai Hyun Park, Seung Hun Hong, Hyun Seok Song, Hye Jun Jin, Sae Ryun Ahn
  • Non-natural Semaphorins 3 and their medical use
    Patent number: 10906948
    Abstract: The present invention relates to non-naturally occurring, mutated Semaphorin 3 molecules. Particularly, the invention relates to the mutated Semaphorin 3 or the functional fragment thereof that exhibit improved properties and pharmacologic effects, e.g., in the treatment of angiogenic disease and cancer. In addition, the present invention relates to nucleic acid molecules encoding such polypeptides, and vectors and hosts comprising such nucleic acids. The invention further relates to methods for producing the polypeptides of the invention, and to methods of using them in the treatment of disease, in particular in the medical intervention of angiogenic diseases, tumors and/or cancer.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: February 2, 2021
    Assignee: Seagull Therapeutics SAS
    Inventors: Guido Serini, Enrico Giraudo, Luca Tamagnone
  • Human G protein alpha subunit gail with at least one mutated amino acid residue
    Patent number: 10899805
    Abstract: The present application discloses in detail mutant ligands of the human G protein alpha-subunit -G?i1-, wherein at least one amino acid residue has been replaced with alanine if the at least one amino acid residue is a non-alanine residue, or at least one amino acid residue has been replace with glycine if the at least one amino acid residue is alanine and wherein the at least one amino acid residue is comprised in a first group containing of the amino acid residues with position R32A, K54A, I55A, I56A, H57A, R176A, E245A, Y296A, T327A, N331A, V332A and D350A or is comprised in a second group containing G42A, A59G, T177A, D200A, A226G, E297A, A300G and F334A or is comprised in a third group containing V50A, A59G, R178A 30 and K180A.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: January 26, 2021
    Assignee: Paul Scherrer Institut
    Inventors: Gebhard Schertler, Dawei Sun, Dmitry Veprintsev
  • Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants
    Patent number: 10894986
    Abstract: The invention features diagnostic and therapeutic methods and compositions featuring androgen receptor variant proteins and nucleic acid molecules whose expression is increased in androgen related diseases or disorders.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: January 19, 2021
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Jun Luo, George Steven Bova, William Isaacs, Thomas Dunn, Rong Hu
  • Fusion proteins comprising enzyme replacement therapy enzymes
    Patent number: 10870837
    Abstract: Provided herein are fusion proteins that comprise an enzyme replacement therapy enzyme and an Fc region, as well as methods of using such proteins to treat a lysosomal storage disorder. Methods for transporting agents across the blood-brain barrier are also provided herein.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: December 22, 2020
    Assignee: Denali Therapeutics Inc.
    Inventors: Anastasia Henry, Mihalis Kariolis, Cathal Mahon, Adam P. Silverman, Ankita Srivastava
  • Antibodies to canine interleukin-4 receptor alpha
    Patent number: 10858437
    Abstract: The present invention discloses antibodies and blocking antibodies to canine IL-4 receptor alpha that have specific sequences and a high binding affinity for canine IL-4 receptor ?. The present invention also discloses the use of the antibodies of the present invention in the treatment of atopic dermatitis in dogs. The present invention further discloses unique epitopes that bind to the antibodies to canine IL-4 receptor alpha.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: December 8, 2020
    Assignee: Intervet, Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang
  • Human alpha-folate receptor chimeric antigen receptor
    Patent number: 10844117
    Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having ?-folate receptor (FR?) binding domain and CD27 costimulatory domain to treat ovarian cancer. In an embodiment, the FR? binding domain is fully human, thereby preventing a host immune response.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: November 24, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Daniel J. Powell, Jr.
  • Phoenixin peptides
    Patent number: 10836812
    Abstract: Human phoenixin peptides, analogs and mimetics useful in production of anti-phoenixin antibodies, diagnostic screening and assays, and in modulating cellular concentration of cAMP, and treatment of disorders related to cAMP or Ca2+ concentration in cells, modulating hypertension and cardiovascular function, modulating gonadotrophs and gastric emptying.
    Type: Grant
    Filed: January 2, 2017
    Date of Patent: November 17, 2020
    Assignee: Phoenix Pharmaceuticals, Inc.
    Inventors: Jaw-Kang Chang, Rong-Ming Lyu
  • Methods for modulating mannose content of recombinant proteins
    Patent number: 10829551
    Abstract: The present invention relates to methods of modulating (e.g., reducing) the mannose content, particularly high-mannose content of recombinant glycoproteins.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: November 10, 2020
    Assignee: Amgen Inc.
    Inventors: Jian Wu, Nicole Sabo, Michael De La Cruz, Gregory Flynn
  • IL-15/IL-15Ralpha based conjugates purification method
    Patent number: 10808022
    Abstract: The present invention relates to a method for preparing a composition comprising monomeric conjugates from a sample, said conjugate comprising (a) a polypeptide comprising the amino acid sequence of interleukin 15 or derivatives thereof, and (b) a polypeptide comprising the amino acid sequence of the sushi domain of IL-15R? or derivatives thereof; wherein said method comprises the use of anion-exchange chromatography followed by a hydrophobic interaction chromatography; and to a pharmaceutical composition which can be obtained by such a method.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: October 20, 2020
    Assignee: Cytune Pharma
    Inventors: David Bechard, Guy de Martynoff
  • Modified proteins and peptides
    Patent number: 10808040
    Abstract: The present disclosure relates to modified proteins and peptides that have reduced ability to bind to pre-existing antibodies. Such modified protein/peptide molecules can comprise C-terminal additions, extensions or tags and/or certain amino acid substitutions. Such modified molecules (e.g., fusions and conjugates) comprise proteins, peptides, antigen binding molecules, antibodies or antibody fragments such as single variable domains. The disclosure further relates to uses and formulations of compositions comprising such modified C-terminally extended and/or amino acid substituted molecules and also to methods of production and expression of these.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: October 20, 2020
    Assignee: Glaxo Group Limited
    Inventors: Claire Ashman, Mary Birchler, Rudolf M. T. De Wildt, Claire Holland, Alan Peter Lewis, Peter Morley, Thomas Sandal, Michael Steward
  • Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent
    Patent number: 10794907
    Abstract: Disclosed is a therapeutic agent for treating a cellular immune disease, comprising as an active ingredient a substance that inhibits binding between Sema3A and a Neuropilin-1/Plexin-A1 heteroreceptor. The substance includes, for example, a Sema3A neutralizing antibody, a Neuropilin-1 neutralizing antibody, or a soluble Neuropilin-1 or derivative thereof. Also disclosed is a method for screening a therapeutic agent for treating a cellular immune disease utilizing a signal generated by the interactions of Neuropilin-1, Plexin-A1 and Sema3A as a marker.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: October 6, 2020
    Assignee: OSAKA UNIVERSITY
    Inventor: Atsushi Kumanogoh
  • Glycoprotein hormone long-acting superagonists
    Patent number: 10766941
    Abstract: This invention provides long-acting, superactive analogs of glycoprotein hormones demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type counterparts. The analogs are particularly useful for treating subjects showing low receptor expression or poor receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: September 8, 2020
    Assignee: Trophogen Inc.
    Inventors: Mariusz Szkudlinski, Bruce D. Weintraub
  • Methods for screening voltage-gated proteins
    Patent number: 10753947
    Abstract: In one aspect, the invention relates to a method for identifying a compound which modulates the activity of a voltage-gated protein. In certain embodiments, the voltage gate protein is a voltage-gated ion channel. In certain embodiments, the voltage-gated protein is a voltage sensitive phosphatase. In certain embodiments, the voltage-gated protein used in conjunction with the methods of the invention is modified to altered permeability or voltage sensitivity.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: August 25, 2020
    Assignee: D.E. SHAW RESEARCH, LLC
    Inventors: Morten Østergaard Jensen, David Wayne Borhani, Vishwanath Jogini
  • Methods for screening voltage-gated proteins
    Patent number: 10739354
    Abstract: In one aspect, the invention relates to a method for identifying a compound which modulates the activity of a voltage-gated protein. In certain embodiments, the voltage gate protein is a voltage-gated ion channel. In certain embodiments, the voltage-gated protein is a voltage sensitive phosphatase. In certain embodiments, the voltage-gated protein used in conjunction with the methods of the invention is modified to altered permeability or voltage sensitivity.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: August 11, 2020
    Assignee: D.E. SHAW RESEARCH, LLC
    Inventors: Morten Østergaard Jensen, David Wayne Borhani, Vishwanath Jogini
  • Methods of treating prostate cancer with GnRH antagonist
    Patent number: 10729739
    Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: August 4, 2020
    Assignee: Ferring B.V.
    Inventors: Tine Kold Olesen, Bo-Eric Persson, Per Cantor, Egbert A van der Meulen, Jens-Kristian Slott Jensen